Stock comparison
Haemonetics
Ironwood Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
IRWD
Ironwood Pharmaceuticals
Market cap
$645.28M
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | IRWD | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 47D | HAE |
| Benjamin Graham | 85A | 25F | HAE |
| Philip Fisher | 60C | 41D | HAE |
| Peter Lynch | 54C | 26F | HAE |
| Joel Greenblatt | 31F | 69B | IRWD |
| Charlie Munger | 54D | 68D | IRWD |
| Terry Smith | 55D | 66C | IRWD |
Side-by-side metrics
| Metric | HAE | IRWD |
|---|---|---|
| Market cap | $2.98B | $645.28M |
| P/E (TTM) | 24.8x | 4.5x |
| EV/EBIT | 14.1x | 9.0x |
| ROIC (TTM) | 8.37% | 43.86% |
| Gross margin | 55.74% | 99.75% |
| Net margin | 7.29% | 41.76% |
| Revenue CAGR 5y | 7.65% | -8.02% |
| EPS CAGR 5y | 24.62% | -53.69% |
| Debt / Equity | 1.5x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Revenue CAGR 5y7.65%vs -8.02%+195%
- EPS CAGR 5y24.62%vs -53.69%+146%
- Market cap$2.98Bvs $645.28M+78%
IRWD leads on
- Debt / Equity-vs 1.5x+156%
- Net margin41.76%vs 7.29%+83%
- P/E (TTM)4.5xvs 24.8x+82%
- ROIC (TTM)43.86%vs 8.37%+81%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.